Degradation of a fluoropyridinyl drug in capsule formulation: Degradant identification, proposed degradation mechanism, and formulation optimization

Pharmaceutical Development and Technology

Volumn 5, Issue 4, 2000, Pages 561-570

  Chen, Jian Ge ^a,b   Markovitz, Debbie A ^b   Yang, Amy Y ^b   Rabel, Shelley R ^b   Pang, Josephine ^b   Dolinsky, Olga ^b   Wu, Lei Shu ^b   Alasandro, Mark ^b  

^a DUPONT COMPANY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Degradation chemistry; DMP 543; Fluoropyridinyl drug; Formulation development

Indexed keywords

10,10 BIS(2 FLUORO 4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; EXCIPIENT; FLUORINE; HYDROXYL GROUP; PYRIDINE DERIVATIVE;

ARTICLE; DRUG CAPSULE; DRUG DEGRADATION; DRUG FORMULATION; DRUG STABILITY; DRUG STRUCTURE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PH; PRIORITY JOURNAL; TEMPERATURE;

ANTHRACENES; CAPSULES; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; EXCIPIENTS; HYDROGEN-ION CONCENTRATION; MASS SPECTROMETRY; NOOTROPIC AGENTS; TEMPERATURE;

EID: 0033672978     PISSN: 10837450     EISSN: None     Source Type: Journal    
DOI: 10.1081/PDT-100102039     Document Type: Article

References (3)

1. Characterization of the solution stability and degradation products of the novel neurotransmitter release enhancer 10, 10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone